Formidable Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Formidable Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,298	Closed	-$383K	–	395
2026 Q1	$383K	Buy	7,298 +3,650	+100%	+$193K	0.06%	272
2025 Q4	$236K	Buy	+3,648	New	+$218K	0.03%	359
2021 Q3	–	Sell	-1,340	Closed	-$217K	–	366
2021 Q2	$217K	Buy	+1,340	New	+$163K	0.05%	279

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Formidable Asset Management's CRSP Position: Q2 2026 in Review

Formidable Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 7,298 shares — an estimated $383K sold.

Formidable Asset Management first reported a position in CRSP in Q2 2021 and held it in 3 quarters. The position peaked at $383K in Q1 2026. 62 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Formidable Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
Formidable Asset Management sold 7,298 CRISPR Therapeutics shares in Q2 2026, an estimated $383K.
Formidable Asset Management first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 3 quarters.
Formidable Asset Management's CRISPR Therapeutics position peaked at $383K in Q1 2026.
62 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Formidable Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.